Main Category: Cervical Cancer / HPV Vaccine
Also Included In: Women's Health / Gynecology
Article Date: 04 May 2011 - 5:00 PDT email to a friend � printer friendly � opinions �
Current Article Ratings:
Patient / Public: | ||
Healthcare Prof: |
As many as one million American women could avoid painful and unnecessary biopsies of the cervix and another estimated 170,000 could potentially be identified with cervical disease up to two years earlier, if technology developed by Guided Therapeutics, Inc. (OTCBB & OTCQB: GTHP) was widely used, according to a presentation made by Dr. Leo B. Twiggs, professor in the Department of Obstetrics and Gynecology at the University of Miami, Miller School of Medicine, to The American College of Obstetricians and Gynecologists (ACOG) Annual Clinical Meeting. The presentation was entitled Study Results of a New Test for Cervical Dysplasia: Potential Impact on Patient Management.
Guided Therapeutics' LuViva Advanced Cervical Scan, which is under U.S. Food and Drug Administration (FDA) premarket approval review, uses light to search for markers of dysplasia, or cervical disease, which may lead to cancer. More than 1,607 women were tested by investigational devices for the pivotal clinical trial necessary for an FDA review.
"We believe that the results, presented by Dr. Twiggs at ACOG, are extremely compelling and demonstrate the potential positive impact the technology could have on women's health," said Mark L. Faupel, Ph.D., CEO and President of Guided Therapeutics, Inc. "As a principal investigator in the clinical trial, Dr. Twiggs is a visionary in this field and was instrumental in the development of the technology."
The LuViva technology, which consists of a base unit and single-patient-use calibration disposable, scans the cervix with light to identify cancer and pre-cancer painlessly and non-invasively. Guided Therapeutics' patented biophotonic technology is able to distinguish between normal and diseased tissue by detecting biochemical and morphological changes at the cellular level. Unlike Pap or HPV tests, the LuViva test would not require laboratory analysis or a tissue sample, is designed to provide results immediately and eliminate costly unnecessary testing.
Source:
ACOG
Guided Therapeutics
Please rate this article: (Hover over the stars then click to rate) | Patient / Public: | or | Health Professional: |
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Privacy Policy | Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd � 2004-2011 All rights reserved.
Source: http://www.medicalnewstoday.com/articles/224204.php
indian women health women and health care pregnant women health womens health vitamins women reproductive health issues
No comments:
Post a Comment